Related Experiment Videos
Isradipine improves platelet function in hypertensives
H Sinzinger1, I Virgolini, F Rauscha
1Wilhelm Auerswald-Atherosclerosis Research Group (ASF), University of Vienna, Austria.
Insights
Isradipine treatment effectively lowered blood pressure and inhibited platelet activation in hypertensive patients. This suggests potential benefits for managing hypertension by addressing both blood pressure and platelet function.
Area of Science:
- Cardiovascular pharmacology
- Hematology
Background:
- Hypertension is a major risk factor for cardiovascular disease.
- Platelet activation plays a significant role in thrombotic events associated with hypertension.
Purpose of the Study:
- To investigate the effects of isradipine on ex vivo platelet function in male hypertensive patients.
- To assess the impact of isradipine on blood pressure and platelet aggregation markers.
Main Methods:
- 10 male hypertensive patients received isradipine (1.25 mg BID for 4 weeks, then 2.5 mg BID for 4 weeks).
- Measurements included blood pressure, platelet aggregation (ADP-induced), serum thromboxane B2, and beta-thromboglobulin at rest and during/after exercise.
- Platelet count and 6-oxo-prostaglandin F1 alpha levels were also assessed.
Main Results:
- Isradipine significantly reduced systolic and diastolic blood pressure.
- Platelet aggregation, serum thromboxane B2, and beta-thromboglobulin levels were significantly decreased.
- Platelet count and 6-oxo-prostaglandin F1 alpha levels remained unaffected.
Conclusions:
- Isradipine effectively lowers blood pressure in hypertensive patients.
- The drug demonstrates inhibitory effects on platelet activation, reducing key markers.
- Combined blood pressure reduction and platelet inhibition suggest potential clinical utility in hypertension management.
Abstract:
The effect of treatment for eight weeks with isradipine 1.25 mg twice daily for 4 weeks and thereafter 2.5 mg twice daily for 4 weeks on ex vivo platelet function was investigated in 10 male hypertensive patients, aged 51 (6.1) y. Systolic and diastolic blood pressure, platelet aggregation in response to ADP, serum thromboxane B2 and beta-thromboglobulin levels were significantly decreased at rest before exercise ergometry, during exercise and at rest after exercise. The platelet count, platelet sensitivity and the plasma levels of 6-oxo-prostaglandin F1 alpha were not affected by isradipine. It is concluded that a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit in the routine treatment of hypertension.